Clinical Trial: RET-Targeted Molecular Imaging Probes in Prostate Cancer

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07886138) titled 'RET-Targeted Molecular Imaging Probes in Prostate Cancer' on Oct. 09.

Brief Summary: The goal of this observational diagnostic imaging study is to evaluate the value of RET-targeted PET/CT molecular imaging in diagnosing neuroendocrine prostate cancer (NEPC) and in assessing disease activity, treatment response, and prognosis. The study population consists of men aged 45-80 years, including approximately 40 patients with suspected or confirmed NEPC (positive group) and approximately 10 patients with conventional prostatic adenocarcinoma (negative control group).

The main questions it aims to answer are:

Can RET-targeted PET/CT ima...